Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis

American Journal of Hypertension
Oliver DörrHolger M Nef

Abstract

Renal sympathetic denervation (RSD) represents an effective treatment option for patients with resistant arterial hypertension (HT). Extracellular matrix (ECM) turnover and deposition are essential processes in HT-related cardiovascular remodeling, fibrosis, and cardiac hypertrophy and contribute to hypertensive heart disease. The primary aim of the present study was to examine the effect of RSD on increased collagen turnover as reflected by serum levels of amino-terminal pro-peptides (PINP, PIIINP) and a carboxyl-terminal pro-peptide (PICP), specific biomarkers for cardiac ECM turnover and cardiovascular fibrosis. A total of 100 consecutive patients (mean age: 65.9±10.1 years) undergoing RSD were included in this study. A therapeutic response was defined as an office systolic blood pressure (SBP) reduction of >10mm Hg 6 months after RSD. Venous serum samples for measurement of PICP, PINP, and PIIINP were collected prior to and 6 months after RSD. A significant reduction in the office SBP of 24.3 mm Hg (SBP baseline: 166.9±14.3 mm Hg (P < 0.001) was documented 6 months after RSD. At this time point, the serum levels of PICP, PINP, and PIIINP (P < 0.01) were significantly decreased compared to baseline values in patients with an...Continue Reading

References

Aug 13, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Allan R BrasierMohsen S Eledrisi
Oct 9, 2002·Circulation·Martin HausbergKarl Heinz Rahn
Jun 3, 2004·Journal of the American College of Cardiology·Begoña LópezJavier Díez
Jan 18, 2005·Lancet·Patricia M KearneyJiang He
Jun 15, 2007·European Heart Journal·Giuseppe Mancia The task force for the management of arterial hypertension of the European Society of Cardiology
Aug 19, 2007·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ulla C KoppTomas Hökfelt
Dec 29, 2007·The Journal of Pathology·T A Wynn
Sep 3, 2008·Cardiovascular Research·Arantxa GonzálezJavier Díez
Jan 28, 2009·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Apr 1, 2014·The New England Journal of Medicine·Deepak L BhattUNKNOWN SYMPLICITY HTN-3 Investigators
Oct 19, 2014·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Oliver DörrHolger Nef
Nov 18, 2014·European Heart Journal·David E KandzariGeorge L Bakris

❮ Previous
Next ❯

Citations

Apr 14, 2016·Kidney Research and Clinical Practice·Márcio G Kiuchi, Decio Mion
Apr 20, 2017·Acta Physiologica·M Carlstrom
Nov 6, 2015·American Journal of Physiology. Renal Physiology·Maria PeleliMattias Carlström
May 19, 2019·International Journal of Molecular Sciences·Márcio Galindo KiuchiMarkus P Schlaich
Feb 25, 2021·Acta Cirúrgica Brasileira·Kamila Aparecida MedeirosJoão Paulo de Arruda Amorim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.